Get in on Jasper Therapeutics Inc.’s (JSPR) buy-in window today!

Jasper Therapeutics Inc. (NASDAQ: JSPR) stock fell -7.25% on Monday to $1.79 against a previous-day closing price of $1.93. With 0.73 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.91 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.0400 whereas the lowest price it dropped to was $1.7600. The 52-week range on JSPR shows that it touched its highest point at $5.81 and its lowest point at $0.39 during that stretch. It currently has a 1-year price target of $6.38.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of JSPR was up-trending over the past week, with a rise of 0.56%, but this was up by 244.23% over a month. Three-month performance surged to 141.89% while six-month performance fell -12.68%. The stock lost -63.17% in the past year, while it has gained 270.68% so far this year. A look at the trailing 12-month EPS for JSPR yields -0.91 with Next year EPS estimates of -1.15. For the next quarter, that number is -0.37. This implies an EPS growth rate of 3.40% for this year and -8.50% for next year.

Float and Shares Shorts:

At present, 36.57 million JSPR shares are outstanding with a float of 25.74 million shares on hand for trading. On Oct 13, 2022, short shares totaled 44760.0, which was 0.12% higher than short shares on Sep 14, 2022. In addition to Dr. Judith Anne Shizuru M.D., Ph.D. as the firm’s Co-Founder, Chair of Scientific Advisory Board & Director, Mr. Jeetinder Singh Mahal M.B.A. serves as its CFO, COO & Corp. Sec.

Institutional Ownership:

Through their ownership of 60.34% of JSPR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 21.99% of JSPR, in contrast to 17.93% held by mutual funds. Shares owned by individuals account for 1.95%. As the largest shareholder in JSPR with 8.68% of the stake, Velan Capital Investment Manageme holds 3,219,036 shares worth 3,219,036. A second-largest stockholder of JSPR, Citadel Advisors LLC, holds 3,102,016 shares, controlling over 8.37% of the firm’s shares. Kingdon Capital Management LLC is the third largest shareholder in JSPR, holding 540,000 shares or 1.46% stake. With a 0.88% stake in JSPR, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 325,773 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.54% of JSPR stock, is the second-largest Mutual Fund holder. It holds 201,831 shares valued at 97484.0. Fidelity Extended Market Index Fu holds 0.21% of the stake in JSPR, owning 76,850 shares worth 37119.0.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for JSPR since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With JSPR analysts setting a high price target of $10.00 and a low target of $3.50, the average target price over the next 12 months is $6.38. Based on these targets, JSPR could surge 458.66% to reach the target high and rise by 95.53% to reach the target low. Reaching the average price target will result in a growth of 256.42% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. JSPR will report FY 2022 earnings on 03/18/2024. Analysts have provided yearly estimates in a range of -$1.02 being high and -$1.12 being low. For JSPR, this leads to a yearly average estimate of -$1.06. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Jasper Therapeutics Inc. surprised analysts by $0.04 when it reported -$0.30 EPS against a consensus estimate of -$0.34. The surprise factor in the prior quarter was $0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.35 and the low estimate is -$0.40. The average estimate for the next quarter is thus -$0.37.

Summary of Insider Activity:

Insiders traded JSPR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 958,444 while 49,486 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *